Clinical risk factors in patients with interstitial lung disease associated with anti-MDA5 autoantibodies

被引:1
作者
Ramos-Martinez, Espiridion [1 ]
Rodriguez-Vega, Eric A. [2 ]
Rivera-Matias, Pedro A. [2 ,3 ]
Falfan-Valencia, Ramces [4 ]
Perez-Rubio, Gloria [4 ]
Mejia, Mayra [2 ]
Gonzalez-Perez, Montserrat I. [2 ]
Buendia-Roldan, Ivette [5 ]
Mateos-Toledo, Heidegger N. [2 ]
Serrano, Jorge Rojas [2 ,6 ]
机构
[1] Univ Nacl Autonoma Mexico, Fac Med, Expt Med Res Unit, Mexico City, Mexico
[2] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Interstitial Lung Dis & Rheumatol Unit, Calzada Tlalpan 4502,Secc 16, Mexico City 14080, Mexico
[3] Becario Direcc Gen Calidad & Educ Salud, Mexico City, Mexico
[4] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Calzada Tlalpan 4502,Secc 16, Mexico City 14080, Mexico
[5] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Res Direct, Calzada Tlalpan 4502,Secc 16, Mexico City 14080, Mexico
[6] Univ Nacl Autonoma Mexico, Fac Med, Programa Maestria & Doctorado Ciencias Med, Mexico City, Mexico
来源
MEDICINA CLINICA | 2023年 / 161卷 / 12期
关键词
Interstitial lung disease; Anti-MDA5; Nonspecific interstitial pneumonia; Inflammatory myopathies; DERMATOMYOSITIS PATIENTS; ANTIBODY; MDA5; RECOGNITION; EXPRESSION;
D O I
10.1016/j.medcli.2023.07.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The anti-MDA5-associated autoimmune disease represents a poorly understood entity. The study's objectives were to describe a cohort of interstitial lung disease (ILD) patients who were positive for anti-MDA5 autoantibody and identify clinical risk factors associated with survival. Methods: This single-center cohort study included ILD patients positive for anti-MDA5 autoantibody. Baseline clinical features were registered, and survival analysis was performed to identify risk factors associated with worse survival. Results: Fifty-three ILD-MDA5 positive patients were included; twelve died during follow-up due to rapidly progressive interstitial lung disease (RP-ILD). Dermatological signs of anti-MDA5 (Gottron papules, Gottron sign, palmar papules, V-neck sign, facial dermatomyositis rashes, and skin ulcers) were strongly associated with death secondary to RP-ILD (HR: 3.7, 95% CI: 1.02-13.35). Patients with dermatological signs were younger, had higher anti-MDA5 autoantibodies titers, more frequent inflammatory patterns in HRCT evaluation, and less fibrosis extent in HRCT. Conclusion: Dermatological manifestation in ILD patients to anti-MDA5 autoantibodies are associated with RP-ILD and short-term fatal outcomes. Dermatological signs may identify a subgroup of ILD-positive to anti-MDA5 patients with a high risk of RP-ILD. (c) 2023 Elsevier Espan similar to a, S.L.U. All rights reserved.
引用
收藏
页码:515 / 522
页数:8
相关论文
共 26 条
[11]   mda-5:: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties [J].
Kang, DC ;
Gopalkrishnan, RV ;
Wu, QP ;
Jankowsky, E ;
Pyle, AM ;
Fisher, PB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (02) :637-642
[12]   Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses [J].
Kato, H ;
Takeuchi, O ;
Sato, S ;
Yoneyama, M ;
Yamamoto, M ;
Matsui, K ;
Uematsu, S ;
Jung, A ;
Kawai, T ;
Ishii, KJ ;
Yamaguchi, O ;
Otsu, K ;
Tsujimura, T ;
Koh, CS ;
Sousa, CRE ;
Matsuura, Y ;
Fujita, T ;
Akira, S .
NATURE, 2006, 441 (7089) :101-105
[13]   Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5 [J].
Kato, Hiroki ;
Takeuchi, Osamu ;
Mikamo-Satoh, Eriko ;
Hirai, Reiko ;
Kawai, Tomoji ;
Matsushita, Kazufumi ;
Hiiragi, Akane ;
Dermody, Terence S. ;
Fujita, Takashi ;
Akira, Shizuo .
JOURNAL OF EXPERIMENTAL MEDICINE, 2008, 205 (07) :1601-1610
[14]   JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study [J].
Le Voyer, Tom ;
Gitiaux, Cyril ;
Authier, Francois-Jerome ;
Bodemer, Christine ;
Melki, Isabelle ;
Quartier, Pierre ;
Aeschlimann, Florence ;
Isapof, Arnaud ;
Herbeuval, Jean Philippe ;
Bondet, Vincent ;
Charuel, Jean-Luc ;
Fremond, Marie-Louise ;
Duffy, Darragh ;
Rodero, Mathieu P. ;
Bader-Meunier, Brigitte .
RHEUMATOLOGY, 2021, 60 (12) :5801-5808
[15]   Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease [J].
Li, Liubing ;
Wang, Qian ;
Wen, Xiaoting ;
Liu, Chenxi ;
Wu, Chanyuan ;
Yang, Funing ;
Zeng, Xiaofeng ;
Li, Yongzhe .
ONCOTARGET, 2017, 8 (44) :76129-76140
[16]   General considerations for lung function testing [J].
Miller, MR ;
Crapo, R ;
Hankinson, J ;
Brusasco, V ;
Burgos, F ;
Casaburi, R ;
Coates, A ;
Enright, P ;
van der Grinten, CPM ;
Gustafsson, P ;
Jensen, R ;
Johnson, DC ;
MacIntyre, N ;
McKay, R ;
Navajas, D ;
Pedersen, OF ;
Pellegrino, R ;
Viegi, G ;
Wanger, J .
EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (01) :153-161
[17]   Antisynthetase Syndrome: A Review of Etiopathogenesis, Diagnosis and Management [J].
Mirrakhimov, Aibek E. .
CURRENT MEDICINAL CHEMISTRY, 2015, 22 (16) :1963-1975
[18]   Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis [J].
Nishioka, Aki ;
Tsunoda, Shinichiro ;
Abe, Takeo ;
Yoshikawa, Takahiro ;
Takata, Miki ;
Kitano, Masayasu ;
Matsui, Kiyoshi ;
Nakashima, Ran ;
Hosono, Yuji ;
Ohmura, Koichiro ;
Mimori, Tsuneyo ;
Sano, Hajime .
MODERN RHEUMATOLOGY, 2019, 29 (05) :814-820
[19]   Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies [J].
Nombel, Anais ;
Fabien, Nicole ;
Coutant, Frederic .
FRONTIERS IN IMMUNOLOGY, 2021, 12
[20]  
Pérez-Padilla R, 2006, ARCH BRONCONEUMOL, V42, P317, DOI 10.1157/13090581